← All themes
Theme

Medical Devices

Every analyzed stock in Medical Devices — 253 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Medical Devices risk
Near-term vs. long-term risk for this theme
⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months
43 /100 Elevated ▲ +1 slight
Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history
66 /100 High ▲ +5 mild
▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.
Inside the "right now" score — a 45 / 30 / 25 blend · 138 stocks valued
Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.
33 Moderate
Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 138 stocks.
51 Elevated
Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.
45 Elevated
Smart money — the three inputs
Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.
49.5%
Elevated
Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.
55%
Elevated
Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.
31%
Moderate
Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 213 stocks (full universe); short-selling is market-wide.
Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.
Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
This week in Medical Devices
Medical Devices — Sep 7 – Sep 11, 2026 (Wk 37): Medical Device Stocks See Elevated Risk Amid Earnings and Valuation Scrutiny →
The medical devices sector experienced an increase in its risk score this week, coinciding with several companies reporting earnings and investors evaluating valuations. While some firms showed profit growth, others faced scrutiny regarding their stock prices…
PLSM
Pulsenmore Ltd.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$2.41
Model IV—
P/IV—
Limited data — see page
PMI
Picard Medical, Inc.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$6.26
Model IV—
P/IV—
Market implies +25.2%/yr vs model +12.5% · above model
POCI
PRECISION OPTICS CORPORATION, INC.
Deeply undervalued
Healthcare Risk 32 · Moderate
Price$4.36
Model IV$9.70
P/IV0.56
Discount 55% Return to IV: +122.4%
Market implies -21.3%/yr vs model +15.6% · below model
PODD
INSULET CORP
Deeply undervalued
Healthcare Risk 24 · Moderate
Price$131.96
Model IV$249.75
P/IV0.58
Discount 47% Return to IV: +89.3%
Market implies +7.4%/yr vs model +20.7% · below model
PRCT
PROCEPT BioRobotics Corp
Deeply undervalued
Healthcare Risk 33 · Moderate
Price$20.38
Model IV$40.36
P/IV0.65
Discount 50% Return to IV: +98.0%
Market implies -12.4%/yr vs model +50.0% · below model
PROF
Profound Medical Corp.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$5.97
Model IV—
P/IV—
Market implies +37.5%/yr vs model +15.0% · above model
PSTV
PLUS THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$3.84
Model IV—
P/IV—
Market implies +70.9%/yr vs model +15.0% · above model
PYPD
PolyPid Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$5.33
Model IV—
P/IV—
Limited data — see page
QTEX
QTREX Quantum Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.89
Model IV—
P/IV—
Market implies +77.0%/yr vs model +15.0% · above model
QTI
QT IMAGING HOLDINGS, INC.
Deeply undervalued
Healthcare Risk 54 · Elevated
Price$2.60
Model IV$3.80
P/IV1.32
Discount 32% Return to IV: +46.1%
Market implies -12.6%/yr vs model +15.0% · below model
RCEL
AVITA Medical, Inc.
Deeply overvalued
Healthcare Risk 59 · Elevated
Price$10.19
Model IV$2.86
P/IV1.51
Premium +256% Return to IV: -71.9%
Market implies +19.0%/yr vs model +24.8% · below model
RDNT
RadNet, Inc.
Fairly valued
Healthcare Risk 43 · Elevated
Price$75.49
Model IV$63.30
P/IV0.88
Premium +19% Return to IV: -16.1%
Market implies +11.3%/yr vs model +11.1% · in line
RGNT
REGENTIS BIOMATERIALS LTD.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.89
Model IV—
P/IV—
Limited data — see page
RMD
RESMED INC
Deeply undervalued
Healthcare Risk 34 · Moderate
Price$218.27
Model IV$375.92
P/IV0.51
Discount 42% Return to IV: +72.2%
Market implies +3.1%/yr vs model +11.9% · below model
RNXT
RenovoRx, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$1.76
Model IV—
P/IV—
Market implies +48.2%/yr vs model +15.0% · above model
RVP
RETRACTABLE TECHNOLOGIES INC
Deeply undervalued
Healthcare Risk 31 · Moderate
Price$0.68
Model IV$1.26
P/IV0.54
Discount 46% Return to IV: +85.3%
Market implies -18.8%/yr vs model +2.0% · below model
RXST
RxSight, Inc.
Deeply undervalued
Healthcare Risk 35 · Moderate
Price$6.02
Model IV$15.21
P/IV0.35
Discount 60% Return to IV: +152.6%
Market implies -15.6%/yr vs model +50.0% · below model
SENS
Senseonics Holdings, Inc.
Deeply overvalued
Healthcare Risk 64 · High
Price$8.71
Model IV$2.41
P/IV2.82
Premium +262% Return to IV: -72.4%
Market implies +22.5%/yr vs model +50.0% · below model
SGHT
Sight Sciences, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$8.14
Model IV—
P/IV—
Market implies +45.4%/yr vs model +12.1% · above model
SGP
SpyGlass Pharma, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$27.52
Model IV—
P/IV—
Limited data — see page
SHC
Sotera Health Co
Deeply overvalued
Healthcare Risk 66 · High
Price$18.37
Model IV$6.60
P/IV2.37
Premium +178% Return to IV: -64.1%
Market implies +19.9%/yr vs model +7.0% · above model
SI
SHOULDER INNOVATIONS, INC.
Deeply undervalued
Healthcare Risk 36 · Moderate
Price$18.53
Model IV$47.55
P/IV0.31
Discount 61% Return to IV: +156.6%
Market implies -17.7%/yr vs model +49.6% · below model
SIBN
SI-BONE, Inc.
Overvalued
Healthcare Risk 56 · Elevated
Price$18.38
Model IV$10.92
P/IV1.29
Premium +68% Return to IV: -40.6%
Market implies +3.9%/yr vs model +22.2% · below model
SINT
Sintx Technologies, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.80
Model IV—
P/IV—
Market implies +29.1%/yr vs model +13.9% · above model
SKIN
SkinHealth Systems Inc.
Deeply undervalued
Healthcare Risk 28 · Moderate
Price$0.70
Model IV$1.53
P/IV0.51
Discount 54% Return to IV: +118.6%
Market implies -10.5%/yr vs model +5.6% · below model
SMTI
Sanara MedTech Inc.
Deeply undervalued
Healthcare Risk 42 · Elevated
Price$34.92
Model IV$68.98
P/IV0.33
Discount 49% Return to IV: +97.5%
Market implies -13.4%/yr vs model +43.8% · below model
SNN
SMITH & NEPHEW PLC
Valuation N/A
Healthcare Risk 27 · Moderate
Price$27.50
Model IV—
P/IV—
Limited data — see page
SNOA
Sonoma Pharmaceuticals, Inc.
Deeply undervalued
Healthcare Risk 29 · Moderate
Price$1.31
Model IV$10.91
P/IV0.10
Discount 88% Return to IV: +735.6%
Market implies -48.8%/yr vs model +2.0% · below model
SNWV
SANUWAVE Health, Inc.
Deeply undervalued
Healthcare Risk 46 · Elevated
Price$4.10
Model IV$23.83
P/IV0.69
Discount 83% Return to IV: +481.3%
Market implies -34.8%/yr vs model +40.3% · below model
SOLV
Solventum Corp
Undervalued
Healthcare Risk 46 · Elevated
Price$87.45
Model IV$99.85
P/IV0.75
Discount 12% Return to IV: +14.2%
Market implies +1.3%/yr vs model +3.6% · in line
SOTK
SONO TEK CORP
Valuation N/A
Industrials Risk 40 · Elevated
Price$4.59
Model IV—
P/IV—
Market implies +24.3%/yr vs model +2.0% · above model
SPAI
Safe Pro Group Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$4.43
Model IV—
P/IV—
Market implies +79.1%/yr vs model +2.0% · above model
SRTA
Strata Critical Medical, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$5.36
Model IV—
P/IV—
Market implies +8.6%/yr vs model +40.6% · below model
SRTS
Sensus Healthcare, Inc.
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$3.13
Model IV$2.09
P/IV1.48
Premium +50% Return to IV: -33.2%
Market implies +0.8%/yr vs model +2.0% · in line
SSII
SS Innovations International, Inc.
Deeply overvalued
Healthcare Risk 57 · Elevated
Price$3.31
Model IV$0.85
P/IV4.66
Premium +291% Return to IV: -74.4%
Market implies +6.9%/yr vs model +15.0% · below model
STAA
STAAR SURGICAL CO
Valuation N/A
Healthcare Risk 37 · Moderate
Price$22.66
Model IV—
P/IV—
Market implies +10.4%/yr vs model +2.0% · above model
STE
STERIS plc
Undervalued
Healthcare Risk 34 · Moderate
Price$210.76
Model IV$269.87
P/IV0.79
Discount 22% Return to IV: +28.0%
Market implies +7.8%/yr vs model +13.6% · below model
STEX
Streamex Corp.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$0.63
Model IV—
P/IV—
Market implies +113.4%/yr vs model +15.0% · above model
STIM
Neuronetics, Inc.
Deeply undervalued
Healthcare Risk 35 · Moderate
Price$3.03
Model IV$2.78
P/IV0.55
Premium +9% Return to IV: -8.3%
Market implies +2.5%/yr vs model +28.2% · below model
STRR
Star Equity Holdings, Inc.
Deeply undervalued
Technology Risk 33 · Moderate
Price$10.40
Model IV$90.50
P/IV0.13
Discount 89% Return to IV: +770.2%
Market implies -50.0%/yr vs model +2.0% · below model
STSS
SkyAI, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$1.31
Model IV—
P/IV—
Market implies +82.5%/yr vs model +15.0% · above model
STVN
Stevanato Group S.p.A.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$20.90
Model IV—
P/IV—
Limited data — see page
STXS
Stereotaxis, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.29
Model IV—
P/IV—
Market implies +46.1%/yr vs model +2.0% · above model
SWKHL
SWK Holdings Corp
Fairly valued
Financial Services Risk 49 · Elevated
Price$25.59
Model IV$23.58
P/IV1.08
Premium +9% Return to IV: -7.8%
Market implies -4.0%/yr vs model -1.4% · in line
SYK
STRYKER CORP
Undervalued
Healthcare Risk 36 · Moderate
Price$281.87
Model IV$362.38
P/IV0.84
Discount 22% Return to IV: +28.6%
Market implies +5.1%/yr vs model +10.1% · below model
SYPR
SYPRIS SOLUTIONS INC
Deeply undervalued
Healthcare Risk 37 · Moderate
Price$1.88
Model IV$6.71
P/IV0.49
Discount 72% Return to IV: +256.7%
Market implies -25.4%/yr vs model +5.3% · below model
TCMD
TACTILE SYSTEMS TECHNOLOGY INC
Deeply undervalued
Healthcare Risk 28 · Moderate
Price$22.40
Model IV$38.96
P/IV0.63
Discount 43% Return to IV: +73.9%
Market implies +1.3%/yr vs model +11.5% · below model
TELA
TELA Bio, Inc.
Deeply undervalued
Healthcare Risk 38 · Moderate
Price$1.04
Model IV$6.38
P/IV0.15
Discount 84% Return to IV: +513.0%
Market implies -41.4%/yr vs model +28.5% · below model
TFX
TELEFLEX INC
Deeply overvalued
Healthcare Risk 66 · High
Price$130.30
Model IV$61.35
P/IV2.10
Premium +112% Return to IV: -52.9%
Market implies +8.1%/yr vs model +2.0% · above model
THQ
abrdn Healthcare Opportunities Fund
Valuation N/A
Unknown
Price$18.92
Model IV—
P/IV—
Limited data — see page
THW
abrdn World Healthcare Fund
Valuation N/A
Unknown
Price$13.39
Model IV—
P/IV—
Limited data — see page
TLSI
TriSalus Life Sciences, Inc.
Deeply overvalued
Healthcare Risk 74 · High
Price$4.78
Model IV$1.56
P/IV2.19
Premium +207% Return to IV: -67.5%
Market implies +11.4%/yr vs model +15.0% · below model
TMCI
TREACE MEDICAL CONCEPTS, INC.
Deeply overvalued
Healthcare Risk 51 · Elevated
Price$4.51
Model IV$2.66
P/IV1.30
Premium +70% Return to IV: -41.0%
Market implies +9.7%/yr vs model +22.5% · below model
TMDX
TransMedics Group, Inc.
Deeply overvalued
Healthcare Risk 57 · Elevated
Price$82.18
Model IV$41.72
P/IV1.61
Premium +97% Return to IV: -49.2%
Market implies +17.6%/yr vs model +10.0% · above model
TNDM
TANDEM DIABETES CARE INC
Fairly valued
Healthcare Risk 49 · Elevated
Price$16.81
Model IV$17.19
P/IV1.00
Discount 2% Return to IV: +2.2%
Market implies -1.7%/yr vs model +9.6% · below model
TNON
Tenon Medical, Inc.
Valuation N/A
Healthcare Risk 41 · Elevated
Price$5.93
Model IV—
P/IV—
Limited data — see page
UFPT
UFP TECHNOLOGIES INC
Deeply undervalued
Healthcare Risk 36 · Moderate
Price$277.89
Model IV$446.42
P/IV0.49
Discount 38% Return to IV: +60.6%
Market implies +11.1%/yr vs model +24.5% · below model
ULBI
ULTRALIFE CORP
Fairly valued
Technology Risk 44 · Elevated
Price$5.60
Model IV$7.49
P/IV0.97
Discount 25% Return to IV: +33.7%
Market implies +6.3%/yr vs model +16.3% · below model
UTMD
UTAH MEDICAL PRODUCTS INC
Undervalued
Healthcare Risk 42 · Elevated
Price$69.71
Model IV$86.32
P/IV0.77
Discount 19% Return to IV: +23.8%
Market implies -0.4%/yr vs model +5.0% · below model
VANI
Vivani Medical, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$1.27
Model IV—
P/IV—
Limited data — see page